Use of elevated ALT alone to identify patients with NAFLD may miss a significant number of patients, as almost 20% of patients with NASH and 25% with NAFLD have a normal ALT [34]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.